Previous Close | 7.57 |
Open | 7.39 |
Bid | 7.75 x 200 |
Ask | 7.78 x 200 |
Day's Range | 7.23 - 7.80 |
52 Week Range | 3.67 - 13.50 |
Volume | |
Avg. Volume | 2,111,868 |
Market Cap | 741.96M |
Beta (5Y Monthly) | -0.08 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.42 |
Earnings Date | May 07, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 16.70 |
SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025 Ended 1Q 2024 with $435.7 million in cash, sufficient to fund operations into 2027 WALTHAM, Mass. and BOULDER, Colo., May 07, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and announced financial results
IND-enabling studies expected to begin mid-2024WALTHAM, Mass. and BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced new preclinical data from the Company’s potent, selective, CNS-penetrant ErbB2 inhibitor program. The data are being presented in a poster session at the American Association for Cancer Research (AACR) 2024 Annual Meeting taki
Bezuclastinib Trials Progress as Cogent Biosciences Inc. Strengthens Cash Position